A Phase 1 Multiple Ascending Dose Study of DS-3201b in Japanese Subjects With Lymphomas
Phase of Trial: Phase I
Latest Information Update: 20 Apr 2018
At a glance
- Drugs DS 3201 (Primary)
- Indications B cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoma; Non-Hodgkin's lymphoma; T cell lymphoma
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Daiichi Sankyo Company
- 19 Jan 2018 Planned End Date changed from 30 Apr 2019 to 1 Apr 2019.
- 19 Jan 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2019.
- 19 Jan 2018 Planned End Date changed from 1 Apr 2018 to 30 Apr 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History